Concepedia

Emily J. Rowling

EJ

Statistics

Publications

9

Citations

640

H-Index

9

Active since

2011

Affiliations

University of Manchester(Current)

Manchester Academic Health Science Centre

Massachusetts General Hospital

The University of Texas MD Anderson Cancer Center

Navarrabiomed

Emily J. Rowling is an author at University of Manchester specializing in oncology, molecular oncology, and medicine.

ORCID

Publications per year

2011–2020

9

Publications

9

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

Amy Peasland, L-Z Wang, Emily J. Rowling et al. · British Journal of Cancer · 2011 · 192 citations · Full text

, , +17

Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing

Zsofia Miskolczi, Michael P. Smith, Emily J. Rowling et al. · Oncogene · 2018 · 129 citations · Full text

, , +17

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition

Helen L. Young, Emily J. Rowling, Mattia Bugatti et al. · The Journal of Experimental Medicine · 2017 · 87 citations · Full text

, , +17

Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure

Michael P. Smith, Emily J. Rowling, Zsofia Miskolczi et al. · EMBO Molecular Medicine · 2017 · 73 citations · Full text

, , +17

GDC-0941 Inhibits Metastatic Characteristics of Thyroid Carcinomas by Targeting both the Phosphoinositide-3 Kinase (PI3K) and Hypoxia-Inducible Factor-1α (HIF-1α) Pathways

Natalie Burrows, Muhammad Babur, Julia Resch et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 63 citations · Full text

, , +15

1–5 of 9